Wednesday, December 22, 2010

Immunodeficiency Disorders

Immunodeficiency Disorders

Immunodeficiency Disorders: INTRODUCTION.

The primary immunologic deficiency diseases include congenital and acquired disorders of humoral immunity (B cell function) or cell-mediated immunity (T cell function). Most of these diseases are rare, and since they are genetically determined, are seen primarily in children. Several immunodeficiency disorders affect adults, and are discussed below. The WHO classification of immunodeficiency disorders more often affecting adults is set forth in the accompanying box.
WHO CLASSIFICATION
Primary Immunodeficiency Disorders:
  Selective IgA deficiency.
  Common variable immunodeficiency.
  X-linked agammaglobulinemia.
  Immunodeficiency with normal serum globulins or hyperimmunoglobulinemia.
  Immunodeficiency with thymoma.
Secondary Immunodeficiency Disorders (for example, AIDS)

Bonilla FA et al. Update on primary immunodeficiency diseases. J Allergy Clin Immunol. 2006 Feb;117(2 Suppl Mini-Primer):S435–41. [PMID: 16455342]
Buckley RH. Primary immunodeficiency or not? Making the correct diagnosis. J Allergy Clin Immunol. 2006 Apr;117(4):756–8. [PMID: 16630930]
Rudd CE. Disabled receptor signaling and new primary immunodeficiency disorders. N Engl J Med. 2006 May 4;354(18):1874–7. [PMID: 16672698]
Selective Immunoglobulin A Deficiency


Selective IgA deficiency is the most common primary immunodeficiency disorder and is characterized by the absence of serum IgA with normal levels of IgG and IgM; its prevalence is about 1:500 individuals. Most persons are asymptomatic because of compensatory increases in secreted IgG and IgM. Some affected patients have frequent and recurrent infections such as sinusitis, otitis, and bronchitis. Some cases of IgA deficiency may spontaneously remit. When IgG2 subclass deficiency occurs in combination with IgA deficiency, affected patients are more susceptible to encapsulated bacteria and the degree of immune impairment can be more severe. Patients with a combined IgA and IgG subclass deficiency should be assessed for functional antibody responses to glycoprotein antigen immunization.
Atopic disease and autoimmune disorders can be associated with IgA deficiency. Occasionally, a sprue-like syndrome with steatorrhea has been associated with an isolated IgA deficit. Treatment with commercial immune globulin is ineffective, since IgA and IgM are present only in trace quantities in these preparations. Frequent infusions of plasma (containing IgA) or unwashed blood transfusions are hazardous, since anti-IgA antibodies may develop, resulting in systemic anaphylaxis or serum sickness.
Woof JM et al. The function of immunoglobulin A in immunity. J Pathol. 2006 Jan;208(2):270–82. [PMID: 16362985]



Common Variable Immunodeficiency

Essentials of Diagnosis
  • Defect in terminal differentiation of B cells, with absent plasma cells and deficient synthesis of secreted antibody.
  • Frequent sinopulmonary infections secondary to humoral immune deficiency.
  • Confirmation by evaluation of serum immunoglobulin levels and deficient functional antibody responses.
General Considerations
The most common cause of panhypogammaglobulinemia in adults is common variable immunodeficiency, a heterogeneous immunodeficiency disorder clinically characterized by an increased incidence of recurrent infections, autoimmune phenomena, and neoplastic diseases. The onset generally is during adolescence or early adulthood but can occur at any age. The prevalence of common variable immunodeficiency is about 1:80,000 in the United States.
Clinical Findings
Symptoms and Signs
The pattern of immunoglobulin isotype deficiency is variable. Most patients present with significantly depressed IgG levels, but over time all antibody classes (IgG, IgA, and IgM) may be affected. Increased susceptibility to pyogenic infections is the hallmark of the disease. Virtually all patients suffer from recurrent sinusitis, with bronchitis, otitis, pharyngitis, and pneumonia also being common infections. Infections may be prolonged or associated with unusual complications such as meningitis or sepsis.
Gastrointestinal disorders are commonly associated with common variable immunodeficiency, and a sprue-like syndrome, with diarrhea, steatorrhea, malabsorption, protein-losing enteropathy, and hepatosplenomegaly, may develop in patients. Paradoxically, there is an increased incidence of autoimmune disease (20%), although patients may not display the usual serologic markers. Autoimmune cytopenias are most common, but autoimmune endocrinopathies, seronegative rheumatic disease, and gastrointestinal disorders are also commonly seen. Lymph nodes may be enlarged in these patients, yet biopsies show marked reduction in plasma cells. Noncaseating granulomas are frequently found in the spleen, liver, lungs, or skin. There is an increased propensity for the development of B cell neoplasms (50- to 400-fold increase risk of lymphoma), gastric carcinomas, and skin cancers.


Laboratory Findings

Diagnosis is confirmed in patients with recurrent infections by demonstration of functional or quantitative defects in antibody production. Serum IgG levels are usually less than 250 mg/dL; serum IgA and IgM levels are also subnormal. Decreased to absent functional antibody responses to protein antigen immunizations establish the diagnosis.
The cause of the panhypogammaglobulinemia in the majority of common variable immunodeficiency patients is an intrinsic B cell defect preventing terminal maturation into antibody-secreting plasma cells. In a small number, excessive suppressor T cell activity that inhibits B cells—or helper T cell activity inadequate to assist B cells to make antibody—has been identified. The absolute B cell count in the peripheral blood in most patients, despite the underlying cellular defect, is normal. A subset of these patients have concomitant T cell immunodeficiency with increased numbers of activated CD8 cells, splenomegaly, and decreased delayed-type hypersensitivity.


Treatment


Patients may be treated aggressively with antibiotics at the first sign of infection. Since antibody deficiency predisposes patients to high-risk pyogenic infections, antibiotic coverage should be sure to cover encapsulated bacteria. Only after the development of bronchiectasis or after sinus surgery do patients become significantly affected by more virulent organisms such as Staphylococcus aureus or Pseudomonas aeruginosa. Maintenance intravenous immune globulin (IGIV) therapy is indicated, with infusions of 300–500 mg/kg of IGIV given at about monthly intervals. Adjustment of dosage or of the infusion interval is made on the basis of clinical responses and steady-state trough serum IgG levels. Such therapy is effective in decreasing the incidence of potentially life-threatening infections and increasing quality of life. The yearly cost of monthly infusions can be in excess of $20,000–$30,000.
Castigli E et al. Molecular basis of common variable immunodeficiency. J Allergy Clin Immunol. 2006 Apr;117(4):740–6. [PMID: 16630927]
Cunningham-Rundles C. Immune deficiency: office evaluation and treatment. Allergy Asthma Proc. 2003 Nov–Dec;24(6):409–15. [PMID: 14763242]
Weiler CR et al. Common variable immunodeficiency: test indications and interpretations. Mayo Clin Proc. 2005 Sep;80(9):1187–200. [PMID: 16178499]


Diseases of Immunoglobulin Overproduction (Gammopathies)


The monoclonal gammopathies include those diseases in which there is a proliferation of a single clone of immunoglobulin-forming cells that produce a homogeneous heavy chain, light chain, or complete molecule. The amino acid sequence of the variable (V) regions is fixed, and only one type ( or ) of light chain is produced. Polyclonal gammopathies result from proliferation of many B cell clones, resulting in a diffuse increase of immunoglobulins.
Monoclonal Gammopathy of Uncertain Significance
Essentials of Diagnosis
  • M protein in the serum without symptoms or signs of multiple myeloma, macroglobulinemia, amyloidosis, or lymphoma.
  • Less than 10% plasma cells in the bone marrow.
General Considerations
The incidence of monoclonal gammopathy of uncertain significance (MGUS) increases with age, and the prevalence may approach 5% in persons 70 years of age or older. Lymphoid malignancies, amyloidosis, macroglobulinemia, or multiple myeloma will develop in as many as one-third of patients with apparently benign monoclonal gammopathies (1% per year). No specific therapy is necessary, but close observation is required. Patients with MGUS should be periodically monitored for changes in serum M proteins, urinary Bence Jones proteins, evidence of renal failure, anemia, hypercalcemia, lytic bone lesions, or bone marrow plasmacytoses. Parameters that suggest a favorable prognosis include (1) concentrations of homogeneous immunoglobulin less than 2 g/dL, (2) no increase in concentration of the immunoglobulin from the time of diagnosis, (3) no decrease in the concentration of normal immunoglobulins, (4) absence of a homogeneous light chain in the urine, and (5) normal hematocrit and serum albumin.


Clinical Findings


Symptoms and Signs

No clinical symptoms are associated with MGUS. In patients with MGUS, the quantity of M protein is stable, and the lymphadenopathy, splenomegaly, or bony lesions seen with multiple myeloma are absent.
Laboratory Findings
The diagnosis of MGUS is made upon finding of a monoclonal spike on serum protein electrophoresis, confirmed by immunoelectrophoresis to be a homogeneous immunoglobulin with either or light chains.
Kyle RA et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006 Mar 30;354(13):1362–9. [PMID: 16571879]
Landgren O et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006 Feb 1;107(3):904–6. [PMID: 16210333]
Rajkumar SV et al. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc. 2006 May;81(5):693–703. [PMID: 16706268]